The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study.
 
Paola Zagami
No Relationships to Disclose
 
Yara Abdou
Honoraria - Cancer Expert Now; Clinical Care Options; Clinical Care Options; MJH Associates; WebMD/Medscape
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Haystack Oncology (Inst); Natera (Inst)
(OPTIONAL) Uncompensated Relationships - Exact Sciences
 
Virginia Delucchi
No Relationships to Disclose
 
Hee Jeong Kim
Honoraria - Alvogen Korea; Takeda
 
Florence Coussy
No Relationships to Disclose
 
Ava Kwong
Honoraria - AstraZeneca; AstraZeneca Hong Kong Limited; AstraZeneca Hong Kong Ltd; Pfizer; Stryker
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme asia limited (Inst); Roche hong kong limited (Inst)
 
Antonio Di Meglio
Expert Testimony - Kephren; techspert.io
 
Giuseppe Curigliano
Leadership - ESMO; ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech
 
Judith Balmaña
No Relationships to Disclose
 
Katarzyna Pogoda
Honoraria - AstraZeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Novartis; Sandoz
Speakers' Bureau - AstraZeneca; Gilead Sciences; Lilly Poland; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Luisina Bruno
Honoraria - Janssen Oncology; Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD Oncology; Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer; Roche; Roche (Inst)
Consulting or Advisory Role - AstraZeneca/Merck; MSD Oncology
Speakers' Bureau - Janssen Oncology; MSD Oncology; roche
Research Funding - Roche
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Novartis; Novartis; Pfizer
 
Ann Partridge
Patents, Royalties, Other Intellectual Property - Wolters Kluwer- royalties for authorship of UpToDate
 
Jeong Eon Lee
No Relationships to Disclose
 
Sabine Linn
Consulting or Advisory Role - AstraZeneca/Merck (Inst); Daiichi Sankyo (Inst)
Research Funding - Agendia (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eurocept Pharmaceuticals (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2022/073958 Method for assessing homologous recombination deficiency in ovarian cancer cells (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH (Inst)
 
Hans Wildiers
Consulting or Advisory Role - Agendia (Inst); Astrazeneca (Inst); Augustine Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Immutep (Inst); Lilly (Inst); MediMix bv (Inst); Menarini (Inst); Novartis (Inst); NV Hict (Inst); Pfizer (Inst); PSI (Inst); Roche (Inst); Seagen (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Lilly (Inst); Gilead Sciences (Inst)
 
Roberto Borea
No Relationships to Disclose
 
Elisa Agostinetto
Honoraria - Abscint (Inst); AstraZeneca; Lilly
Consulting or Advisory Role - AstraZeneca (Inst)
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Abscint; AstraZeneca; AstraZeneca; Daiichi Sankyo Europe GmbH; Genetic Spa; Novartis
 
Lisa Carey
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); NanoString Technologies (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Veracyte (Inst)
(OPTIONAL) Uncompensated Relationships - Reveal Genomics
 
Eva Blondeaux
No Relationships to Disclose
 
Matteo Lambertini
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Ipsen; Knight Therapeutics; Libbs; Lilly; Menarini; Novartis; Pfizer; Roche; Sandoz; Takeda
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Gilead Sciences; Roche